SCHEMBL17889803

CC(=O)N[C@@H]1[C@@H]([C@H](O)[C@H](O)CO)O[C@](O[C@@H]2[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](CO[C@]4(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O4)O[C@@H](O[C@H]4[C@@H](O)[C@@H](CO)O[C@@H](OCCCCCN)[C@@H]4O)[C@@H]3NC(C)=O)O[C@H](CO)[C@@H]2O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2NC(C)=O)(C(=O)O)C[C@H]1O

nearest known ligand 0.72

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	SIGLEC7	Q9Y286	6/20	0.72

▸	MAG	P20916	9/20	0.64

▸	SELL	P14151	1/20	0.52

▸	SELP	P16109	1/20	0.52

▸	SELE	P16581	3/20	0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL17897215	1.00	SIGLEC7 (0.72)	SIGLEC7MAGSELLSELPSELE
SCHEMBL21043887	0.96	SIGLEC7 (0.67)	SIGLEC7MAGSELLSELPSELE
SCHEMBL17897191	0.96	SIGLEC7 (0.67)	SIGLEC7MAGSELLSELPSELE
SCHEMBL16381360	0.96	SIGLEC7 (0.67)	SIGLEC7MAGSELLSELPSELE
SCHEMBL17889799	0.96	SIGLEC7 (0.67)	SIGLEC7MAGSELLSELPSELE
SCHEMBL17897339	0.96	SIGLEC7 (0.67)	SIGLEC7MAGSELLSELPSELE
SCHEMBL16381105	0.96	SIGLEC7 (0.69)	SIGLEC7MAGSELLSELPSELE
SCHEMBL17897338	0.96	SIGLEC7 (0.69)	SIGLEC7MAGSELLSELPSELE
SCHEMBL16381089	0.96	SIGLEC7 (0.76)	SIGLEC7MAGSELLSELPSELE
SCHEMBL21043896	0.96	SIGLEC7 (0.76)	SIGLEC7MAGSELLSELPSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-3013365-B1	RM2 ANTIGENS AND USE THEREOF	ACADEMIA SINICA (TW)	2019-06-05	—	—	EP	disclosed
US-10086054-B2	RM2 antigens and use thereof	ACADEMIA SINICA (TW)	2018-10-02	—	—	US	disclosed
US-20160193310-A1	RM2 ANTIGENS AND USE THEREOF	ACADEMIA SINICA	2016-07-07	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20160193310-A1	RM2 ANTIGENS AND USE THEREOF	LGALS2, MAN2B2, GALNT2	SIGLEC7 6/4885MAG 74/4885SELL 683/4885
US-10086054-B2	RM2 antigens and use thereof	MAN2B2, LGALS2, GALNT2	SIGLEC7 6/4885MAG 72/4885SELL 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.